For women with premature ovarian insufficiency, continuous use of combined oral contraceptives is associated with increased BMD, similar to that seen with high-dose hormone therapy.
Positive topline data were announced from two phase 3 studies evaluating the efficacy and safety of linzagolix (Yselty®; ObsEva) for the treatment of heavy menstrual bleeding due to uterine fibroids.
Positive topline results were announced from the phase 3 SPIRIT 1 study investigating relugolix (Myovant Sciences), in combination with estradiol and norethindrone acetate, in women with pain associated with endometriosis.
Combination therapy with insulin sensitizers may be superior to monotherapy for improvement of hyperandrogenemia and menstrual recovery in polycystic ovary syndrome.
The FDA has approved Oriahnn™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules; AbbVie) for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.
Compared with children who are naturally conceived, children who are conceived via assisted reproductive techniques (ART) may be at increased risk for mortality during their first year of life.
Researchers examined factors associated with returning to the use of assisted reproductive therapy for a second child and cycle-specific and cumulative live birth rates.
In a study, most symptomatic hypogonadal men treated with Natesto, a short-acting 4.5% nasal testosterone gel, attained normal testosterone levels at 6 months while preserving sperm counts.
Postmenopausal women with both bilateral salpingo-oophorectomy and a family history of premature myocardial infarction have an increased risk for heart disease mortality, especially those who underwent BSO at an earlier age.
